What taper schedule should I use when switching a patient from sertraline (Zoloft) 150 mg to citalopram?

Switching from Sertraline 150 mg to Citalopram: Taper Strategy

When switching from sertraline 150 mg to citalopram, use a gradual cross-taper approach: reduce sertraline by 25-50 mg every 1-2 weeks while simultaneously starting citalopram at 20 mg once the sertraline dose reaches 75-100 mg, then continue tapering sertraline to discontinuation over 4-6 weeks total.

Rationale for Cross-Tapering

Both sertraline and citalopram are SSRIs with similar mechanisms of action, which allows for a direct switch strategy 1, 2. However, abrupt discontinuation of sertraline at 150 mg carries significant risk of withdrawal symptoms, as the FDA labels explicitly warn that "adverse reactions may occur upon discontinuation" and recommend gradual dose reduction rather than abrupt cessation 1.

Specific Taper Schedule

Week 1-2:

• Sertraline: 150 mg → 100 mg daily
• Citalopram: None yet
• Rationale: Initial 25-50 mg reduction as recommended by FDA labeling 1

Week 3-4:

• Sertraline: 100 mg → 50 mg daily
• Citalopram: Start 20 mg daily
• Rationale: Begin citalopram at therapeutic dose (20 mg is the FDA-recommended starting dose) 2 while continuing sertraline taper

Week 5-6:

• Sertraline: 50 mg → 25 mg daily
• Citalopram: Continue 20 mg daily

Week 7-8:

• Sertraline: 25 mg → discontinue
• Citalopram: Continue 20 mg daily (may increase to 40 mg if needed after week 8)

Critical Considerations

Avoid alternate-day dosing: Recent evidence demonstrates that dosing antidepressants every other day during tapering causes pronounced receptor occupancy variation and significantly increases withdrawal risk 3. This approach cannot be recommended despite its common use in practice.

Dose equivalence context: Based on systematic analysis of randomized trials, sertraline 98.5 mg is approximately equivalent to fluoxetine 40 mg, while citalopram dosing differs 4. Your patient on sertraline 150 mg is on a moderate-to-high dose, making gradual tapering essential.

Withdrawal risk factors: Sertraline carries moderate risk for withdrawal symptoms compared to other SSRIs 5. The 24-hour elimination half-life of sertraline 1 means weekly dose reductions are appropriate, as recommended by FDA labeling.

Monitoring During the Switch

• Weekly assessment for withdrawal symptoms (dizziness, paresthesias, anxiety, irritability, insomnia, flu-like symptoms)
• If withdrawal symptoms emerge, slow the taper rate or temporarily hold at current doses
• Monitor for depressive symptom worsening, particularly during weeks 3-6 when both medications are being adjusted

Pitfalls to Avoid

1. Do not stop sertraline abruptly when starting citalopram—this risks severe withdrawal despite starting another SSRI
2. Do not use alternate-day dosing as a tapering strategy 3
3. Do not exceed citalopram 40 mg/day due to QT prolongation risk 2
4. Do not rush the taper—if the patient has been on sertraline long-term, consider extending the taper to 8-12 weeks 5, 6

Special Populations

• Age >60 years: Maximum citalopram dose is 20 mg/day due to QT prolongation risk 2
• Hepatic impairment: Maximum citalopram dose is 20 mg/day 2
• CYP2C19 poor metabolizers: Maximum citalopram dose is 20 mg/day 2

The cross-taper approach balances the need to avoid withdrawal symptoms from sertraline discontinuation while establishing therapeutic coverage with citalopram, minimizing the risk of depressive relapse during the transition period.